Effects of Dexrazoxane and Amifostine on Evolution of Doxorubicin Cardiomyopathy In Vivo

  title={Effects of Dexrazoxane and Amifostine on Evolution of Doxorubicin Cardiomyopathy In Vivo},
  author={Sne{\vz}ana K. Bjelogrli{\'c} and Jelena Radi{\'c} and Sini{\vs}a S Radulovi{\'c} and Milan Jokanovi{\'c} and Viktor Jovi{\'c}},
  journal={Experimental Biology and Medicine},
  pages={1414 - 1424}
Doxorubicin is one of the most active drugs in oncology, with cardiotoxicity as a serious side effect of its application. The aim of this study was to investigate dexrazoxane and amifostine impact on the evolution of myocardial changes induced by doxorubicin. BalbC female mice were treated with doxorubicin only (10 mg/kg, single intravenous push), or with dexrazoxane (200 mg/kg, intraperitoneal [ip]) or amifostine (200 mg/kg, ip) 60 mins or 30 mins prior to treatment with doxorubicin… 

Figures and Tables from this paper

Activity of Dexrazoxane and Amifostine Against Late Cardiotoxicity Induced by the Combination of Doxorubicin and Cyclophosphamide In Vivo
Results revealed that the cardiotoxicity of DC combination displays specific morphological hallmark and evolution in time, different to those described after doxorubicin single treatment.
Prevention and Treatment of Doxorubicin-Induced Cardiotoxicity by Dexrazoxane and Schisandrin B in Rabbits
Schisandrin B had dose-dependent effects in decreasing the magnitude of doxorubicin-induced indicators of cardiomyopathy to a degree that approximated the decrease produced by dexrazoxane treatment.
The protection of the myocardium by amifostine against mitoxantrone-induced acute cardiotoxicity in rats.
AMI can protect against MITO-induced acute cardiotoxicity, decreasing myocardial damage and lipid peroxidation, and the myocardium increased catalase and GSH levels to prevent this damage.
Effect of Dexrazoxane and Amifostine on the Vertebral Bone Quality of Doxorubicin Treated Male Rats
It is shown that when male rats are treated with DOX, DXR, DOX+DXR, AMF,DOX+AMF or DOX +DXR+AMf, there is a decrease in lumbar vertebral BMD, which will be useful in designing better cancer combination therapies that do not lead to vertebrae deterioration.
Development of doxorubicin-induced chronic cardiotoxicity in the B6C3F1 mouse model.
Doxorubicin-Induced Cardiotoxicity: From Mechanisms to Development of Efficient Therapy
The incidence of DOX-induced cardiotoxicity (DIC); the progress made over the past four decades in understanding the molecular mechanisms of the pathogenesis of acute and chronic DIC; the current strategies for heart protection; and the major breakthroughs and challenges in basic and clinical research to the development of efficient targeted therapy for DIC are described.
The cardioprotective effect of AMI was superior to LC in terms of myocardial degeneration, atrial fibrosis and ventricular fibrosis.
The impact of doxorubicin and dexrazoxane injection of prepubertal female rats on pregnancy outcome and cardiac function postpartum.
The eccentric hypertrophy and dilation development, despite compensatory changes in proteins controlling calcium cycling, suggest DOX damage with repeat pregnancy that was not alleviated fully by DEX.


Efficiency of amifostine as a protection against doxorubicin toxicity in rats during a 12-day treatment.
Seven and 20 mg/kg amifostine protected rats from the toxicity of doxorubicin at the cumulative dose of 18mg/kg during a 12-day treatment, with regard to weight loss and heart contraction.
Amifostine protection against doxorubicin cardiotoxicity in rats
Since AMI had very good protective effects against a high dose of DOX given as a multiple, low, unitary dose regimen, not only on the heart but on the whole rat as well, it could be recommended for further investigation in this potentially new indication for clinical application.
Amifostine improves hemodynamic parameters in doxorubicin-pretreated rabbits.
It is shown that pretreatment with doxorubicin at the total dose of 12 mg/kg significantly reduced CI and increased TPR in doxorbicin-pretreated rabbits, and amifostine improved CI and TPR on average in these animals.
Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats
Compared to dexrazoxane, amifostine provided a comparable degree of protection against the nephrotoxicity of doxorubicin, but was less cardioprotective and did not prevent the mortality and loss of body weight produced by doxorbicin.
Cardioprotection by dexrazoxane (Cardioxane; ICRF 187): Progress in supportive care
  • K. Hellmann
  • Medicine, Biology
    Supportive Care in Cancer
  • 2005
The results of all these trials lead to the conclusion that DXRz permits cardiotoxic doses of doxorubicin to be given without cardiotoxicity and patients with increased cardiac risk factors to be treated with full doses of dioxorubsicin.
Dexrazoxane. A review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy.
Preliminary results indicate that dexrazoxane reduces cardiac toxicity in children and adolescents receiving anthracycline-based therapy for a range of malignancies and permits the administration of doxorubicin beyond standard cumulative doses; however, it is unclear whether this will translate into prolonged survival.
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
Cutting peak plasma levels of doxorubicin by continuous infusion reduces cardiotoxicity, and thus lessen cardiac toxicity, in patients treated by standard intravenous injection.
The protective effects of amifostine on adriamycin-induced acute cardiotoxicity in rats.
Results indicate that amifostine decreases adriamycin-induced lipid peroxidation and increases the levels of the protective enzymes in the heart tissue, and may ameliorate the adri amycin- induced acute cardiotoxicity.
Amifostine protects against early but not late toxic effects of doxorubicin in infant rats.
The present results suggest that more data from growing immature animal models are needed to analyze the safety of amifostine treatment and its mechanisms of action before wider clinical use of this drug in pediatric cancer patients is recommended.